AVIEW Lung Nodule CAD vs FibriCheck

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW Lung Nodule CAD

by Coreline Soft Co.

FibriCheck

by Qompium nv

AI Verdict

AVIEW Lung Nodule CAD is an AI-powered software for radiologists, focusing on the detection and analysis of pulmonary nodules, COPD, and coronary artery calcification from CT scans. FibriCheck, on the other hand, is a patient-facing mobile application that uses smartphone technology for remote heart rhythm monitoring to detect arrhythmias. While both leverage AI in cardiology, they serve distinct purposes: AVIEW for advanced diagnostic imaging analysis and FibriCheck for continuous physiological monitoring.

Choose AVIEW Lung Nodule CAD if…

Choose AVIEW Lung Nodule CAD if your radiology department requires an advanced AI-powered solution to enhance the accuracy and efficiency of pulmonary nodule detection and analysis on chest CT scans. This tool is ideal for comprehensive screening programs that simultaneously assess lung cancer risk, COPD, and coronary artery calcification, providing detailed quantitative analysis and automated reporting for radiologists.

View AVIEW Lung Nodule CAD →

Choose FibriCheck if…

Choose FibriCheck if you need a user-friendly, patient-centric solution for remote heart rhythm monitoring and early arrhythmia detection using a smartphone. This app is best suited for empowering patients to actively track their cardiac health and for healthcare providers to remotely monitor at-risk individuals, facilitating timely intervention and ongoing management of conditions like Atrial Fibrillation.

View FibriCheck →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW Lung Nodule CAD	FibriCheck
Pricing	Contact for pricing	Available via subscription for end-users (monthly/yearly) or through licensing agreements for healthcare providers and clinical centers.
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	Cloud-based digital application
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FibriCheck

FibriCheck's patient-facing mobile app, utilizing a common device like a smartphone, offers a highly accessible and intuitive user experience for its target audience. While AVIEW enhances a radiologist's workflow, FibriCheck's direct-to-consumer and patient-centric design generally implies broader and simpler usability for its end-users.

Clinical Value

Tie

Both tools provide substantial clinical value by addressing critical needs in their respective medical fields. AVIEW offers comprehensive AI-powered analysis for early detection and management of lung cancer, COPD, and coronary artery calcification from CT scans, while FibriCheck empowers patients with smartphone-based arrhythmia detection and remote monitoring, both contributing significantly to patient outcomes and preventive care.

Pricing & Value

FibriCheck

FibriCheck offers transparent and publicly disclosed pricing models for both end-users and healthcare providers, allowing for clear cost-benefit analysis. AVIEW's pricing is not publicly disclosed, making it challenging to assess its value proposition without direct inquiry.

Enterprise Readiness

AVIEW Lung Nodule CAD

AVIEW offers superior enterprise readiness due to its flexible deployment options, including cloud-based, hybrid, local hardware, and virtualized solutions, which can accommodate diverse and complex IT infrastructures found in large healthcare organizations. While FibriCheck is cloud-based and offers a professional portal, its deployment flexibility is more limited.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. AVIEW's 'Big 3' simultaneous analysis of lung nodules, emphysema, and coronary artery calcification from a single CT scan represents a novel approach to comprehensive thoracic screening. FibriCheck's utilization of a standard smartphone camera for medically certified heart rhythm monitoring and arrhythmia detection is a groundbreaking application of consumer technology for remote patient care.

Support & Docs

FibriCheck

FibriCheck offers a more transparent and accessible support ecosystem, including a dedicated online Help Center with user manuals for both patients and healthcare providers, FAQs, and comprehensive developer documentation. While AVIEW mentions user manuals and technical brochures, FibriCheck's resources appear more readily available and structured for diverse user needs.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW Lung Nodule CAD	FibriCheck
Name	AVIEW Lung Nodule CAD	FibriCheck
Company	Coreline Soft Co.	Qompium nv
Primary Focus	Assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery calcification.	Helps patients monitor their heart rhythm to detect and monitor arrhythmias using just their smartphone.
Core AI-driven Capabilities	AI-based pulmonary nodule detection (3-20 mm), nodule classification, 3D nodule size and volume quantification, automatic report generation (Lung-RADS), nodule matching and volume doubling time (VDT) calculation, simultaneous analysis of lung nodules, emphysema, and coronary artery calcification.	AI-powered algorithm for arrhythmia detection and analysis, detection of Atrial Fibrillation (AFib) and other arrhythmias using smartphone camera-based PPG technology.
Target User / Monitoring Approach	Assists radiologists in clinical settings for diagnostic support.	Patient-facing mobile application for self-monitoring, with a healthcare professional portal/dashboard for patient monitoring.
Additional Health Metrics / Analysis	Quantitative emphysema analysis (e.g., Low Attenuation Area - LAA, emphysema index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass scores).	Ability to log blood pressure and weight.

Videos

Demos, reviews, and walkthroughs featuring AVIEW Lung Nodule CAD and FibriCheck.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply does each tool integrate with existing EHR and imaging systems to streamline clinical workflows and ensure seamless data exchange?

AVIEW Lung Nodule CAD is designed to integrate into radiology workflows, complying with DICOM standards for linking with PACS and providing a user interface for analyzing, identifying, storing, and transmitting quantified values. FibriCheck offers a healthcare professional portal with API-based integration into existing EHRs and RPM platforms, allowing clinicians to create prescriptions and monitor patient heart rhythm directly within their workflow.

What are the validated accuracy and sensitivity metrics for each tool in its respective clinical application, particularly for subtle findings or specific disease types?

AVIEW Lung Nodule CAD has demonstrated a sensitivity of 97% and specificity of 76% for lung nodule detection, with a 34% increase in sensitivity and a 70% reduction in reading time for radiologists. FibriCheck has shown excellent accuracy for detecting Atrial Fibrillation (AF), with a sensitivity of 98.3% and specificity of 99.9% in external validation studies, and an overall accuracy of 98.5% in a multicenter study.

Beyond the listed specialties, what specific clinical scenarios or patient populations would most benefit from each tool's unique capabilities?

AVIEW Lung Nodule CAD is particularly beneficial for high-volume lung cancer screening programs and incidental finding management, aiding radiologists and pulmonologists in early detection and follow-up, and simultaneously analyzing emphysema and coronary artery calcification. FibriCheck excels in remote monitoring for patients at risk of or diagnosed with arrhythmias, empowering cardiologists and primary care physicians to continuously track heart rhythm, detect transient events, and manage conditions between visits.

What is the expected learning curve for clinical staff to become proficient with each tool, and what is the typical time-to-value for realizing its benefits in a clinical setting?

For AVIEW Lung Nodule CAD, the learning curve involves understanding AI-generated detections and classifications, with time-to-value realized through increased efficiency in nodule analysis and reporting, potentially reducing radiologist workload by up to 86.7%. FibriCheck's user-friendly mobile application and professional portal suggest a relatively quick onboarding for both patients and clinicians, leading to rapid value in remote patient monitoring and early arrhythmia detection, with staff finding it easy to onboard patients in less than five minutes.

What are the practical considerations and support available for deploying each tool across multiple clinical sites or a large healthcare system?

AVIEW Lung Nodule CAD has been deployed across multiple sites and selected for government-led lung cancer screening projects in Europe, indicating support for multi-site rollouts and integration with diverse PACS environments. FibriCheck is built to scale from one person to millions, offering API-based integration and support for RPM-ready workflows, with proven deployment across 25,000+ members with one insurance partner.